Press release
Investigation announced for Investors who lost money with shares of Senti Biosciences, Inc. (NASDAQ: SNTI)
An investigation for investors in Senti Biosciences, Inc. (NASDAQ: SNTI) shares over potential securities laws violations.
Investors who purchased shares of Senti Biosciences, Inc. (NASDAQ: SNTI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Senti Biosciences, Inc. (NASDAQ: SNTI) concerning whether a series of statements by Senti Biosciences, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 25, 2021, Dynamics Special Purpose Corp. (NASDAQ: DYNS) held its initial public offering (IPO) at $10.00 per share and raised $200 million.
Then on December 20, 2021, Dynamics Special Purpose Corp announced it was engaging in a $601 million de-SPAC transaction with Senti Biosciences, Inc.
The transaction closed on June 8, 2022 and the combined company was renamed Senti Biosciences, Inc. (NASDAQ: SNTI).
Shares of Senti Biosciences, Inc. (NASDAQ: SNTI) declined to as low as $0.271 per share on April 22, 2024.
Those who purchased shares of Senti Biosciences, Inc. (NASDAQ: SNTI) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Senti Biosciences, Inc. (NASDAQ: SNTI) here
News-ID: 3496690 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (N …
An investor, who purchased shares of Tronox Holdings plc (NYSE: TROX), filed a lawsuit over alleged violations of Federal Securities Laws by Tronox Holdings plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Tronox Holdings plc (NYSE: TROX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 3, 2025. NYSE: TROX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in Petco Health and Wellness Company, Inc. …
An investigation was announced for current long-term investors in shares of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) concerning potential breaches of fiduciary duties by certain directors of Petco Health and Wellness Company, Inc.
Investors who are current long term investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation…
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) …
An investigation was announced for current long-term investors in shares of RxSight, Inc. (NASDAQ: RXST) concerning potential breaches of fiduciary duties by certain directors of RxSight, Inc.
Investors who are current long term investors in RxSight, Inc. (NASDAQ: RXST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RXST…
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 202 …
A deadline is coming up on October 3, 2025 in the lawsuit filed for certain investors of Tesla, Inc. (NASDAQ: TSLA) over alleged securities laws violations by Tesla, Inc.
Investors who purchased shares of Tesla, Inc. (NASDAQ: TSLA) have certain options and there are strict and short deadlines running. Deadline: October 3, 2025. Tesla, Inc. (NASDAQ: TSLA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Senti
NK Cell Therapy Market Poised for Transformative Growth by 2034: Insights on Cli …
DelveInsight has released its latest market analysis report titled "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034", delivering a comprehensive view of the evolving therapeutic landscape of Natural Killer (NK) cell therapy across the 7 Major Markets (7MM) - the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
The report provides an in-depth understanding of current treatment practices, emerging NK cell therapies, market size trends, clinical…
Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the Acute Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
CD33-targeted Antibody Drug Conjugates Market Size, Clinical Trials, Product Pip …
CD33-targeted Antibody Drug Conjugates Market Size is estimated to be $121 million in 2024 and is expected to grow at an average yearly rate of around 12% during the timeframe (2025-2032).
What is CD33-targeted Antibody Drug Conjugates and what are the growth drivers of CD33-targeted Antibody Drug Conjugates Market?
CD33-targeted Antibody Drug Conjugates (ADCs) are a class of precision cancer therapeutics that combine the targeting ability of monoclonal antibodies with…
NK Cell Therapy Therapeutics Market Size in 7MM is expected to grow at a decent …
DelveInsight's "NK Cell Therapy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the NK Cell Therapy, historical and forecasted epidemiology as well as the NK Cells therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the NK Cell Therapy Market Share @ NK Cell Therapy Market Outlook- https://www.delveinsight.com/sample-request/nk-cell-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
NK Cell Therapy Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medicati …
NK cell therapy companies are Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences, and others
(Albany, USA) DelveInsight's NK Cell Therapy Market Insights report includes a comprehensive understanding of current treatment practices, emerging NK cell therapy, market share of individual therapies, and current and forecasted NK cell therapy market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom,…
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Me …
DelveInsight's, "Acute Myeloid Leukemia Pipeline Insight" report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive…
